A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

BACKGROUND: Lisdexamfetamine dimesylate (LDX) is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6 to 12 years of age and in adults. In a previous laboratory school study, LDX demonstrated efficacy 2 hours postdose with duration of efficacy through 12 hours...

Descripción completa

Detalles Bibliográficos
Autores principales: Wigal, Sharon B, Kollins, Scott H, Childress, Ann C, Squires, Liza
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704174/
https://www.ncbi.nlm.nih.gov/pubmed/19508731
http://dx.doi.org/10.1186/1753-2000-3-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704174/
https://www.ncbi.nlm.nih.gov/pubmed/19508731
http://dx.doi.org/10.1186/1753-2000-3-17

Ejemplares similares